In medical physics and radiobiology, the most common method to probe the efficacy of radiation therapy approaches in vitro is the cell survival trial. Recently, the traditional procedure for external beams has been extended by some groups to targeted radionuclides. In parallel, the bioengineering state of the art allows for the use of 3D tissue-mimicking scaffolds to obtain realistic cell cultures in dynamic conditions. The aim of this study is to implement a mathematical model for the assessment of β-emitting radiopharmaceuticals, considering their molecular kinetics in vitro and how it affects the radiation delivery to cells. The molecular transitions will be assumed to fulfill the definition of Markov processes, while the cell survival will depend on the DNA damage, in competition with a logistic growth. The solutions of the resulting differential system will be evaluated by means of numerical examples. This work belongs to the framework of the ISOLPHARM project, headed by INFN-LNL, which has the aim of developing innovative radiopharmaceuticals exploiting the Isotope Separation On-Line (ISOL) at the SPES facility.

Arzenton, A. (2023). Radiobiological model for β-emitter radiopharmaceutical therapy in dynamic cell cultures in the framework of the ISOLPHARM project. IL NUOVO CIMENTO C, 46(03) [10.1393/ncc/i2023-23072-3].

Radiobiological model for β-emitter radiopharmaceutical therapy in dynamic cell cultures in the framework of the ISOLPHARM project

Arzenton, Alberto
2023-01-01

Abstract

In medical physics and radiobiology, the most common method to probe the efficacy of radiation therapy approaches in vitro is the cell survival trial. Recently, the traditional procedure for external beams has been extended by some groups to targeted radionuclides. In parallel, the bioengineering state of the art allows for the use of 3D tissue-mimicking scaffolds to obtain realistic cell cultures in dynamic conditions. The aim of this study is to implement a mathematical model for the assessment of β-emitting radiopharmaceuticals, considering their molecular kinetics in vitro and how it affects the radiation delivery to cells. The molecular transitions will be assumed to fulfill the definition of Markov processes, while the cell survival will depend on the DNA damage, in competition with a logistic growth. The solutions of the resulting differential system will be evaluated by means of numerical examples. This work belongs to the framework of the ISOLPHARM project, headed by INFN-LNL, which has the aim of developing innovative radiopharmaceuticals exploiting the Isotope Separation On-Line (ISOL) at the SPES facility.
2023
Arzenton, A. (2023). Radiobiological model for β-emitter radiopharmaceutical therapy in dynamic cell cultures in the framework of the ISOLPHARM project. IL NUOVO CIMENTO C, 46(03) [10.1393/ncc/i2023-23072-3].
File in questo prodotto:
File Dimensione Formato  
ncc12642.pdf

accesso aperto

Tipologia: PDF editoriale
Licenza: Creative commons
Dimensione 407.66 kB
Formato Adobe PDF
407.66 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11365/1236334